Crestline Management, LP Denali Therapeutics Inc. Transaction History

Crestline Management, LP

$1.88 Billion
Q3 2024

A detailed history of Crestline Management, LP transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Crestline Management, LP holds 4,460,732 shares of DNLI stock, worth $110 Million. This represents 6.91% of its overall portfolio holdings.

Number of Shares

4,460,732

Previous 4,760,732 6.3%

Holding current value

$110 Million

Previous $111 Million 17.55%

% of portfolio

6.91%

Previous 8.67%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$20.96 - $31.05 $6.29 Million - $9.32 Million	-300,000 Reduced 6.3%	4,460,732 $130 Million
Q2 2024 Aug 13, 2024	SELL	$14.96 - $23.22 $6.73 Million - $10.4 Million	-450,000 Reduced 8.64%	4,760,732 $111 Million
Q1 2024 May 14, 2024	SELL	$15.83 - $23.35 $7.12 Million - $10.5 Million	-450,000 Reduced 7.95%	5,210,732 $107 Million
Q4 2023 Feb 12, 2024	SELL	$16.2 - $23.18 $4.86 Million - $6.95 Million	-300,000 Reduced 5.03%	5,660,732 $121 Million
Q3 2023 Nov 14, 2023	SELL	$20.63 - $30.17 $3.09 Million - $4.53 Million	-150,000 Reduced 2.45%	5,960,732 $123 Million
Q2 2023 Aug 14, 2023	SELL	$23.37 - $32.96 $7.01 Million - $9.89 Million	-300,000 Reduced 4.68%	6,110,732 $180 Million
Q1 2023 May 15, 2023	SELL	$21.91 - $32.67 $9.86 Million - $14.7 Million	-450,000 Reduced 6.56%	6,410,732 $148 Million
Q4 2022 Feb 13, 2023	SELL	$26.28 - $33.92 $7.88 Million - $10.2 Million	-300,000 Reduced 4.19%	6,860,732 $191 Million
Q3 2022 Nov 14, 2022	SELL	$25.97 - $38.53 $7.79 Million - $11.6 Million	-300,000 Reduced 4.02%	7,160,732 $220 Million
Q1 2022 May 16, 2022	SELL	$29.0 - $47.27 $7.08 Million - $11.5 Million	-244,307 Reduced 3.17%	7,460,732 $240 Million
Q3 2021 Nov 12, 2021	SELL	$48.48 - $78.23 $20.9 Million - $33.7 Million	-430,442 Reduced 5.29%	7,705,039 $389 Million
Q2 2021 Aug 13, 2021	SELL	$50.3 - $78.44 $93 Million - $145 Million	-1,849,355 Reduced 18.52%	8,135,481 $638 Million
Q1 2021 May 14, 2021	SELL	$53.8 - $81.53 $510 Million - $773 Million	-9,477,664 Reduced 48.7%	9,984,836 $570 Million
Q4 2020 Feb 12, 2021	BUY	$36.89 - $93.56 $268 Million - $679 Million	7,260,866 Added 59.51%	19,462,500 $339 Million
Q3 2020 Nov 13, 2020	SELL	$23.13 - $38.84 $33.4 Million - $56.1 Million	-1,443,247 Reduced 10.58%	12,201,634 $437 Million
Q2 2020 Aug 14, 2020	SELL	$16.01 - $28.82 $30.8 Million - $55.4 Million	-1,922,855 Reduced 12.35%	13,644,881 $330 Million
Q1 2020 May 13, 2020	SELL	$14.2 - $27.98 $55.3 Million - $109 Million	-3,894,764 Reduced 20.01%	15,567,736 $273 Million
Q4 2018 Feb 14, 2019	SELL	$13.88 - $21.75 $15.4 Million - $24.2 Million	-1,111,799 Reduced 5.4%	19,462,500 $402 Million
Q1 2018 May 15, 2018	BUY	$15.36 - $24.8 $15 - $24	1 Added 0.0%	20,574,299 $405 Million
Q4 2017 Feb 14, 2018	BUY	$15.04 - $21.45 $309 Million - $441 Million	20,574,298	20,574,298 $322 Million

Others Institutions Holding DNLI

# of Institutions

228

Shares Held

120M

Call Options Held

60.6K

Put Options Held

48.4K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.31B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Crestline Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Crestline Management, LP with notifications on news.

Account

Crestline Management, LP Denali Therapeutics Inc. Transaction History